» Articles » PMID: 11513892

In Vitro Responses of Praziquantel-resistant and -susceptible Schistosoma Mansoni to Praziquantel

Overview
Journal Int J Parasitol
Specialty Parasitology
Date 2001 Aug 22
PMID 11513892
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

The resistance status of five praziquantel-susceptible and five praziquantel-resistant isolates was confirmed by chemotherapy in CD(1) mice with 3 x 200mg/kg micronised praziquantel. Micronised praziquantel had higher efficacy than two other praziquantel formulations (prepared without milling). The five resistant isolates were less responsive to praziquantel than the five susceptible isolates (59-74% reduction in worm burden in resistant isolates compared with 92-100% in susceptible isolates). Observations were made on the in vitro responses of different stages of 10 isolates to praziquantel. There were different in vitro responses to praziquantel at the egg, miracidial, cercarial and adult stages of Schistosoma mansoni between praziquantel-resistant and praziquantel-susceptible isolates. There were differences in the response of resistant and susceptible isolates following exposure of freshly hatched miracidia to 10(-6)M praziquantel for 1 min and observing the percent change in shape. Using this test it should be possible to determine whether failed therapy in patients infected with S. mansoni is due to the presence of praziquantel-resistant worms. Similarly, by exposing freshly shed cercariae to 4 x 10(-7)M praziquantel and observing the percent of tail shedding over 80 min it should be possible to monitor for the presence of praziquantel-resistant worms in snails collected in the field.

Citing Articles

Small change, big difference: A promising praziquantel derivative designated P96 with broad-spectrum antischistosomal activity for chemotherapy of schistosomiasis japonica.

Xu J, Dong L, Sun H, Huang P, Zhang R, Wang X PLoS Negl Trop Dis. 2023; 17(7):e0011215.

PMID: 37410790 PMC: 10353801. DOI: 10.1371/journal.pntd.0011215.


Bioorganometallic Compounds as Novel Drug Targets against Schistosomiasis in Sub-Saharan Africa: An alternative to Praziquantel?.

Ndamse C, Masamba P, Kappo A Adv Pharm Bull. 2022; 12(2):283-297.

PMID: 35620337 PMC: 9106956. DOI: 10.34172/apb.2022.029.


Praziquantel-encapsulated niosomes against Schistosoma mansoni with reduced sensitivity to praziquantel.

Amer E, Abou-El-Naga I, Boulos L, Ramadan H, Younis S Biomedica. 2022; 42(1):67-84.

PMID: 35471171 PMC: 9059922. DOI: 10.7705/biomedica.5913.


Two-year longitudinal survey reveals high genetic diversity of Schistosoma mansoni with adult worms surviving praziquantel treatment at the start of mass drug administration in Uganda.

Faust C, Crotti M, Moses A, Oguttu D, Wamboko A, Adriko M Parasit Vectors. 2019; 12(1):607.

PMID: 31881923 PMC: 6935072. DOI: 10.1186/s13071-019-3860-6.


Niosomes for enhanced activity of praziquantel against Schistosoma mansoni: in vivo and in vitro evaluation.

Zoghroban H, El-Kowrany S, Aboul Asaad I, El Maghraby G, El-Nouby K, Abd Elazeem M Parasitol Res. 2018; 118(1):219-234.

PMID: 30421348 DOI: 10.1007/s00436-018-6132-z.